Literature DB >> 11315460

Respiratory infection in the chronically critically ill patient. Ventilator-associated pneumonia and tracheobronchitis.

Q A Ahmed1, M S Niederman.   

Abstract

The long-term ventilated patient is at high risk for developing nosocomial pneumonia or tracheobronchitis. In general, the frequency of infection increases with the duration of mechanical ventilation, but the risk appears to be greatest in the first week of intubation. Although these types of infection are common and may have morbidity and mortality impact, the daily risk is less in the long-term ventilated patient than in the acutely ill intubated patient. This reduced daily risk may reflect a "survivor effect," with less healthy patients dying early in the hospital stay and not surviving long enough to undergo tracheostomy and long-term ventilation. A number of factors predispose these patients to infection, including host defense impairment and exposure to large numbers of bacteria. This exposure can occur through the airway, and proper care of respiratory therapy devices is essential to minimize the risk for infection. Most infections of the lower respiratory tract are preceded by airway colonization with EGN bacteria and, with improvement in host defenses and nutrition, infection in the face of colonization is less likely. In some patients, colonization can be eliminated. When the long-term ventilated patient does develop infection, it generally involves highly resistant gram-negative or gram-positive organisms and therapy should be prompt and appropriate. Not all such patients respond to systemic antibiotics, and the use of adjunctive aerosol therapy may have benefit for those with either tracheobronchitis or pneumonia, especially if highly resistant pathogens are present.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11315460     DOI: 10.1016/s0272-5231(05)70026-5

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  13 in total

1.  Roles of interleukin-6 in activation of STAT proteins and recruitment of neutrophils during Escherichia coli pneumonia.

Authors:  Matthew R Jones; Lee J Quinton; Benjamin T Simms; Michal M Lupa; Mariya S Kogan; Joseph P Mizgerd
Journal:  J Infect Dis       Date:  2005-12-27       Impact factor: 5.226

2.  The Lung-Liver Axis: A Requirement for Maximal Innate Immunity and Hepatoprotection during Pneumonia.

Authors:  Kristie L Hilliard; Eri Allen; Katrina E Traber; Kazuko Yamamoto; Nicole M Stauffer; Gregory A Wasserman; Matthew R Jones; Joseph P Mizgerd; Lee J Quinton
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

3.  Epithelial LIF signaling limits apoptosis and lung injury during bacterial pneumonia.

Authors:  Elim Na; Eri Allen; Lillia A Baird; Christine V Odom; Filiz T Korkmaz; Anukul T Shenoy; Adeline M Matschulat; Matthew R Jones; Darrell N Kotton; Joseph P Mizgerd; Xaralabos Varelas; Katrina E Traber; Lee J Quinton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-02-09       Impact factor: 6.011

4.  Mechanisms of the hepatic acute-phase response during bacterial pneumonia.

Authors:  Lee J Quinton; Matthew R Jones; Bryanne E Robson; Joseph P Mizgerd
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

5.  Activation of Hepatic STAT3 Maintains Pulmonary Defense during Endotoxemia.

Authors:  Kristie L Hilliard; Eri Allen; Katrina E Traber; Yuri Kim; Gregory A Wasserman; Matthew R Jones; Joseph P Mizgerd; Lee J Quinton
Journal:  Infect Immun       Date:  2015-07-27       Impact factor: 3.441

6.  Alveolar epithelial STAT3, IL-6 family cytokines, and host defense during Escherichia coli pneumonia.

Authors:  Lee J Quinton; Matthew R Jones; Bryanne E Robson; Benjamin T Simms; Jeffrey A Whitsett; Joseph P Mizgerd
Journal:  Am J Respir Cell Mol Biol       Date:  2008-01-10       Impact factor: 6.914

7.  Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: a case-control study.

Authors:  Saad Nseir; Christophe Di Pompeo; Stéphane Soubrier; Hélène Lenci; Pierre Delour; Thierry Onimus; Fabienne Saulnier; Daniel Mathieu; Alain Durocher
Journal:  Crit Care       Date:  2005-03-31       Impact factor: 9.097

8.  Myeloid ZFP36L1 does not regulate inflammation or host defense in mouse models of acute bacterial infection.

Authors:  Lynnae D Hyatt; Gregory A Wasserman; Yoon J Rah; Kori Y Matsuura; Fadie T Coleman; Kristie L Hilliard; Zachary Ash Pepper-Cunningham; Michael Ieong; Deborah J Stumpo; Perry J Blackshear; Lee J Quinton; Joseph P Mizgerd; Matthew R Jones
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

9.  Ventilator-associated pneumonia in patients on prolonged mechanical ventilation: description, risk factors for mortality, and performance of the SOFA score.

Authors:  Sebastián Ariel Núñez; Guillermina Roveda; Mariela Soledad Zárate; Mónica Emmerich; María Teresa Verón
Journal:  J Bras Pneumol       Date:  2021-06-23       Impact factor: 2.800

10.  Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study.

Authors:  Saad Nseir; Raphaël Favory; Elsa Jozefowicz; Franck Decamps; Florent Dewavrin; Guillaume Brunin; Christophe Di Pompeo; Daniel Mathieu; Alain Durocher
Journal:  Crit Care       Date:  2008-05-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.